XML 16 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS
3 Months Ended
Mar. 31, 2013
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS [Abstract]  
COLLABORATIVE RESEARCH AND DEVELOPMENT AGREEMENTS
NOTE3 — COLLABORATIVE RESEARCH AND DEVELOPMENT ARRANGEMENTS:
 
 
a)  
  National Institutes of Health (NIH) Grant:
In June 2009, the Company received a $2.8 million, three-year grant from the United States National Institutes of Health to complete development of a test for Leptospirosis.  Grants are invoiced after expenses are incurred.   The Company earned none and $155,000 for the three-month periods ended March 31, 2013 and 2012, respectively from this grant. The Company earned an aggregate of $2,756,000 from this grant from inception through March 31, 2013, of which $898,000 was paid to sub-contractors.
 
In March 2011, the Company received a $2.9 million, three-year grant from the United States National Institutes of Health to complete development of a test for Tuberculosis.  Grants are invoiced after expenses are incurred.  The Company earned $192,000 and $125,000 for the three-month periods ended March 31, 2013 and 2012, respectively from this grant. The Company earned $1,644,000 from this grant from inception through March 31, 2013 of which $419,000 was paid to sub-contractors.
 
b)  
Battelle/CDC DPP® Influenza Immunity Test:
In July 2012, the Company entered into a follow-on, milestone-based development agreement of up to $480,000 based on Chembio's previous successful initial development of a multiplex rapid point-of-care ("POC") influenza immunity test utilizing its patented Dual Path Platform (DPP®) technology. The agreement contemplates a period of approximately nine months in which the follow-on development activity is to be completed.  The Company earned $166,000 and none for the three-month periods ended March 31, 2013 and 2012, respectively from this agreement. The Company earned $444,000 from this grant from inception through March 31, 2013.